ReviewHepatology international2026
New therapies for primary biliary cholangitis.
Review in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary Biliary Cholangitis (PBC) is a cholestatic autoimmune liver disease of small bile ducts. Ursodeoxycholic acid (UDCA) was approved as a first line therapeutic option for PBC in 1997. It was later noted that 40% of patients with PBC are either non-responders or intolerant to UDCA. In 2016, obeticholic acid (OCA) was approved as a second-line therapy for PBC. However, due to the side effects associated with OCA and the FDA restricting its use in patients with cirrhosis, there was a need for additional therapies.
aimsThis review summarizes the current literature regarding the new and emerging therapies for patients with PBC. KEY
findingsIn 2024, two new therapies, elafibranor and seladelpar were approved as a second-line treatment for PBC. In 2025 OCA was withdrawn from the market. Multiple additional therapies targeting biochemical remission are under investigation. Furthermore, a new class of medication, ileal bile acid transporter inhibitors (IBAT inhibitors), is being studied for pruritus among these patients.
conclusionThe therapeutic landscape for PBC has been rapidly evolving with the discovery of second-line agents. Ongoing trials studying biochemical response, symptom control and long-term clinical outcomes among patients with PBC will be beneficial.
Indexed as
Identifiers
42101777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.